Inclusion Criteria:

- Histologically documented ovarian cancer, primary peritoneal carcinoma or fallopian
tube carcinoma that has recurred > 6 months after platinum-based chemotherapy

- This must be the first recurrence of the epithelial ovarian cancer, primary
peritoneal carcinoma or fallopian tube carcinoma

- Are at least two weeks but no more than 3 months after the completion of second-line
cytotoxic chemotherapy

- Are currently under observation or being treated with bevacizumab as a second-line
maintenance therapy

- Have a valid email address and access to the internet

- Provide voluntary written informed consent

- Speak and read English fluently

Exclusion Criteria:

- Current participation in a blinded clinical trial for ovarian cancer treatment.
(Participation in a trial involving only supportive care medicines and/or growth
factors is acceptable)

- Another primary diagnosis of cancer in a different site